PT-141 Palatin.
Journal: Current Opinion In Investigational Drugs (London, England : 2000)
Published:
Abstract
Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.
Authors
Petter Hedlund
Relevant Conditions